TP03HN106 in Patients With Critical Limb Ischemia

Phase 2

Recruiting

• Conditions: Critical Limb Ischemia
• Interventions: Drug: TP03HN106

• Registration Number: NCT06482892
• Lead Sponsor: Talengen Institute of Life Sciences, Shenzhen, P.R. China.

Brief Summary

Critical limb ischemia (CLI) is the most severe ischemic stage in peripheral arterial disease (PAD) of the lower limbs, characterized by decreased walking ability, resting pain (lasting for more than 2 weeks), ulcers, and gangrene, which seriously affect the quality of life of patients. Some patients may even face amputation or death. Thrombosis is an important pathological feature of CLI. TP03HN106 can promote thrombolysis, thus having a therapeutic effect on CLI.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-06-20
• Study First Submitted QC: 2024-06-25
• Study First Posted: 2024-07-01
• Study Start: 2024-07-18
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-10
• Last Update Posted: 2025-04-15
• Primary Completion: 2025-09-30
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. When signing the informed consent form, the age should be ≥ 18 years old, regardless of gender;
2. Clinically diagnosed as a patient with Critical limb ischemia, with a Rutherford score of 4-6.
3. Patients who are unable to undergo interventional surgical treatment, or whose previous interventional surgical treatment is ineffective, or who are unwilling to undergo any intervention or surgical treatment, and can only receive conventional antiplatelet and vasodilator drugs (before baseline, antiplatelet and vasodilator drugs must be used for at least 1 week);
4. During the screening period, lower limb artery color ultrasound or lower limb computed tomography angiography (CTA) showed severe stenosis or occlusion of one or more of the common iliac artery, external iliac artery, common femoral artery, superficial femoral artery, popliteal artery, anterior tibial artery, posterior tibial artery, and fibular artery;
5. During the screening period, if there are severe symptoms of lower limb ischemia, meeting any of the following symptoms is sufficient: There is limb rest pain caused by lower limb ischemia, with a disease duration of ≥ 2 weeks, and a VAS score of ≥ 40mm and < 100mm before the first administration; There are limb tissue ulcers caused by lower limb ischemia, with a disease duration of ≥ 2 weeks and limb ulcers (4cm2 ≤ maximum single ulcer area ≤ 25cm2);
6. All subjects with fertility or their spouses must take effective contraceptive measures within 3 months after signing the informed consent form until the completion of the trial;
7. The subjects voluntarily give informed consent and sign an informed consent form (if the subjects and/or their guardians lack reading ability and cannot understand the content of the informed consent, they need to sign together with a fair witness), fully understand the methods and procedures of the experiment, and be able to provide biological samples for testing related indicators in accordance with the experiment requirements.

Exclusion Criteria

1. Subjects who are known to be allergic to the investigational drug, its excipients, or other human blood products;
2. Patients with limb gangrene greater than 4 cm2;
3. Patients currently suffering from malignant tumor diseases (including those who have previously had malignant tumors but have not been cured);
4. Screening period for patients with liver and kidney failure:
5. Patients who require hemodialysis;
6. Those who have experienced cerebral infarction or cerebral hemorrhage within 3 months prior to signing the informed consent form;
7. During the screening period, subjects with mental illness, obvious mental disorders or epilepsy, including other individuals with no behavioral or cognitive abilities;
8. Hypertensive patients (SBP ≥ 160mmHg and/or DBP ≥ 100mmHg) who cannot be controlled after standardized treatment in the screening period;
9. Individuals who have received fresh plasma, cold precipitates, or blood products containing TP03HN106 components within one month prior to signing the informed consent form;
10. Those who have participated in clinical trials of other drugs or medical devices within one month before signing the informed consent form;
11. Those who have undergone or plan to undergo surgery during the trial period within one month prior to signing the informed consent form;
12. Alcoholism and/or psychoactive substances, drug abusers and dependents (alcoholism standard: the weekly alcohol intake is more than 21 units (male) and 14 units (female) (1 unit=360 mL beer; or 150 mL wine; or 45 mL white spirit);
13. Miscarriage or termination of pregnancy less than 3 months prior to signing the informed consent form, pregnant women and lactating women (currently breastfeeding or not artificially breastfeeding but less than 6 months after delivery);
14. Poor compliance or any other situation that the researcher deems unsuitable for inclusion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment group	TP03HN106	-

Primary Outcome Measures

Name	Time	Method
Overall clinical treatment efficacy rate	Day 62	The VAS score or ulcer area decreases by ≥ 50% compared to baseline when administering day 62, it is considered a clinically effective case.; The overall clinical efficacy of patient treatment is calculated according to the following formula: Overall clinical treatment effectiveness rate=(number of clinically effective cases/total cases) × 100% When the calculated overall clinical success rate is ≥ 70%, the entire clinical trial is considered successful.

Secondary Outcome Measures

Name	Time	Method
Ankle brachial index, ABI	Baseline, day 6, day 21, day 34, day 49, and day 62	Changes in ABI of subjects (applicable to patients with ulcers) compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62 ABI:The ratio of ankle artery systolic pressure to ipsilateral brachial artery systolic pressure
TcPO2	Baseline, day 6, day 21, day 34, day 49, and day 62	Changes in TcPO2 of subjects (applicable to patients with ulcers) compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62 TcPO2: transcutaneous oxygen partial pressure
TBI	Baseline, day 6, day 21, day 34, day 49, and day 62	Changes in TBI of subjects compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62 TBI: The ratio of toe artery systolic pressure to ipsilateral brachial artery systolic pressure
Overall clinical treatment efficacy rate	Day 6, day 14, day 21, day 34, day 49	The VAS score or ulcer area decreases by ≥ 50% compared to baseline when administering day 6, day 14, day 21, day 34, day 49, it is considered a clinically effective case.; The overall clinical efficacy of patient treatment is calculated according to the following formula: Overall clinical treatment effectiveness rate=(number of clinically effective cases/total cases) × 100% When the calculated overall clinical success rate is ≥ 70%, the entire clinical trial is considered successful.
Rutherford grading	Baseline, day 6, day 21, day 34, day 49, and day 62	Changes in Rutherford grading of subjects compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62

Trial Locations

Locations (1)

The First Affiliated Hospital of Soochow University; 🇨🇳 Suzhou, Jiangsu, China